Article Text

Download PDFPDF

Impact of national smoke-free legislation on home smoking bans: findings from the International Tobacco Control Policy Evaluation Project Europe Surveys
  1. Ute Mons1,2,
  2. Gera E Nagelhout3,4,
  3. Shane Allwright5,
  4. Romain Guignard6,
  5. Bas van den Putte7,
  6. Marc C Willemsen3,4,
  7. Geoffrey T Fong8,9,
  8. Hermann Brenner2,
  9. Martina Pötschke-Langer1,
  10. Lutz P Breitling2
  1. 1Unit Cancer Prevention and WHO Collaborating Centre for Tobacco Control, German Cancer Research Center (DKFZ), Heidelberg, Germany
  2. 2Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
  3. 3Maastricht University/CAPHRI School for Public Health and Primary Care, Maastricht, the Netherlands
  4. 4STIVORO for a smoke-free future, The Hague, the Netherlands
  5. 5Department of Public Health and Primary Care, Trinity College, Dublin, Ireland
  6. 6French Institute for Health Promotion and Health Education (INPES), Saint-Denis, France
  7. 7Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, the Netherlands
  8. 8Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada
  9. 9Ontario Institute for Cancer Research, Toronto, Ontario, Canada
  1. Correspondence to Ute Mons, German Cancer Research Center, Unit Cancer Prevention and WHO Collaborating Centre for Tobacco Control, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; u.mons{at}dkfz.de

Footnotes

  • Funding ITC Ireland: US National Cancer Institute (R01 CA90955), Glaxo Smith Kline, Flight Attendants' Medical Research Institute, Pfizer (Ireland) and Cancer Research UK. ITC France: French Institute for Health Promotion and Health Education (INPES), French National Cancer Institute (INCa), French Monitoring Centre for Drugs and Drug Addiction (OFDT). ITC Netherlands: The Netherlands Organisation for Health Research and Development (ZonMw). ITC Germany: German Ministry of Health, German Cancer Research Center, Dieter-Mennekes-Umweltstiftung. ITC UK: US National Cancer Institute (RO1 CA100362 and P50 CA111236), Canadian Institutes of Health Research (57897), Cancer Research UK (C312/A6465). Survey development, management and data management, ITC Project, University of Waterloo: US National Cancer Institute (P50 CA111236; P01 CA138389); Canadian Institutes of Health Research (57897; 79551); Ontario Institute of Cancer Research. UM was financially supported by Klaus Tschira Foundation gGmbH. GTF was supported by a Senior Investigator Award from the Ontario Institute for Cancer Research and a Prevention Scientist Award from the Canadian Cancer Society Research Institute.

  • Competing interests None.

  • Ethics approval The study was approved by Research Ethics Board of the University of Waterloo, Ontario, Canada.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Technical reports, questionnaires and National Reports are available on www.itcproject.org.

View Full Text

Statistics from Altmetric.com

Supplementary materials

  • HTML Page - index.htslp

    Files in this Data Supplement:

Footnotes

  • Funding ITC Ireland: US National Cancer Institute (R01 CA90955), Glaxo Smith Kline, Flight Attendants' Medical Research Institute, Pfizer (Ireland) and Cancer Research UK. ITC France: French Institute for Health Promotion and Health Education (INPES), French National Cancer Institute (INCa), French Monitoring Centre for Drugs and Drug Addiction (OFDT). ITC Netherlands: The Netherlands Organisation for Health Research and Development (ZonMw). ITC Germany: German Ministry of Health, German Cancer Research Center, Dieter-Mennekes-Umweltstiftung. ITC UK: US National Cancer Institute (RO1 CA100362 and P50 CA111236), Canadian Institutes of Health Research (57897), Cancer Research UK (C312/A6465). Survey development, management and data management, ITC Project, University of Waterloo: US National Cancer Institute (P50 CA111236; P01 CA138389); Canadian Institutes of Health Research (57897; 79551); Ontario Institute of Cancer Research. UM was financially supported by Klaus Tschira Foundation gGmbH. GTF was supported by a Senior Investigator Award from the Ontario Institute for Cancer Research and a Prevention Scientist Award from the Canadian Cancer Society Research Institute.

  • Competing interests None.

  • Ethics approval The study was approved by Research Ethics Board of the University of Waterloo, Ontario, Canada.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Technical reports, questionnaires and National Reports are available on www.itcproject.org.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.